Latest topics page 27
Topics ordered by most recent activity across all 71 subcategories.
1,535 topics · page 27 of 52
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Hepatic steatosis: what the MASH trial evidence supports — one year on
On the subject in the title: Hepatic steatosis: what the MASH trial evidence supports — one year on Working notes rather than a conclusion. General question, not a request for advice about my own care — I…
|
2 | 4.1k | 6mo | |
|
Coming back to: Private prescribing in the UK: what is actually involved
Private prescribing in the UK: what is actually involved Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that…
|
+62 | 67 | 2.1k | 6mo |
|
Distinguishing expected GI effects from something that needs urgent attention
Distinguishing expected GI effects from something that needs urgent attention Writing it up because I had to work it out twice and would rather nobody else did. Reporting something rather than asking about…
|
+88 | 101 | 32k | 6mo |
|
Early satiety becoming a problem rather than a benefit
Early satiety becoming a problem rather than a benefit — setting out what I have, and where I think it stops being reliable. A question about technique rather than about dose. I have been doing the same thing…
|
+20 | 24 | 2.5k | 6mo |
|
Aggregates and why a purity assay may miss them entirely
Aggregates and why a purity assay may miss them entirely Writing it up because I had to work it out twice and would rather nobody else did. A documentation question rather than an analytical one. I have a…
|
+61 | 69 | 2.9k | 6mo |
|
Coming back to: "Greater than or equal to 99%" as a specification rather than a result
Posting this under the heading it deserves: "Greater than or equal to 99%" as a specification rather than a result Everything below is what sits behind that. Working through the identity arithmetic and I…
|
2 | 31k | 6mo | |
|
Why "add 2 mL" is not an instruction
The question in the title: Why "add 2 mL" is not an instruction I will give what I have already checked below so nobody repeats it. A question about technique rather than about dose. I have been doing the…
|
+23 | 27 | 3.5k | 6mo |
|
A partial dose because the pen emptied mid-injection
A partial dose because the pen emptied mid-injection Writing it up because I had to work it out twice and would rather nobody else did. Practical question with the units stated, because I have seen how…
|
+108 | 120 | 1.5k | 7mo |
|
Guidelines revision: what changed and why — does this still hold?
Guidelines revision: what changed and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Process question about how this site works. I have…
|
2 | 58k | 7mo | |
|
Temperature logging at home: what is worth the effort
Temperature logging at home: what is worth the effort — setting out what I have, and where I think it stops being reliable. Practical question with the units stated, because I have seen how quickly these go…
|
2 | 6.3k | 7mo | |
|
Why oral semaglutide needs an absorption enhancer at all
Why oral semaglutide needs an absorption enhancer at all I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of…
|
+59 | 65 | 61k | 7mo |
|
Coming back to: Payment mechanics and the recovery options that do not exist
On the subject in the title: Payment mechanics and the recovery options that do not exist Working notes rather than a conclusion. Structured report rather than an opinion, following the format the maintainers…
|
+7 | 11 | 2.6k | 7mo |
|
Second pass at: MALDI versus ESI for a quick identity check
Second pass at: MALDI versus ESI for a quick identity check Writing it up because I had to work it out twice and would rather nobody else did. Working through the identity arithmetic and I would like it…
|
2 | 18k | 7mo | |
|
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing SURPASS-4 ( Lancet , 2021)…
|
+130 | 135 | 11k | 7mo |
|
[2026 update] Reflux appearing for the first time at a dose step
Posting this under the heading it deserves: Reflux appearing for the first time at a dose step Everything below is what sits behind that. Reporting something rather than asking about it, in case the pattern…
|
2 | 980 | 7mo | |
|
The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset
Posting this under the heading it deserves: The 2.5 mg starting dose is not a therapeutic dose — why that matters — a second dataset Everything below is what sits behind that. Session topic: STEP 8 ( JAMA ,…
|
+12 | 16 | 11k | 7mo |
|
Appeal templates and why they are deliberately unemotional
Posting this under the heading it deserves: Appeal templates and why they are deliberately unemotional Everything below is what sits behind that. Documenting an access outcome, dated, because everything in…
|
+25 | 29 | 764 | 7mo |
|
CJC-1295 with and without DAC: what the modification does — what changed since
CJC-1295 with and without DAC: what the modification does — what changed since Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024)…
|
4 | 5.1k | 7mo | |
|
How to read a forest plot, properly, from scratch
The question in the title: How to read a forest plot, properly, from scratch I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read it before…
|
+73 | 81 | 17k | 7mo |
|
Why one laboratory's 98.4% and another's 96.1% may not contradict
Why one laboratory's 98.4% and another's 96.1% may not contradict I have a specific reason for asking rather than idle curiosity, and the context is below. A documentation question rather than an analytical…
|
+28 | 37 | 457 | 7mo |
|
Retatrutide's phase 2 heart-rate signal and how to think about it
On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…
|
+19 | 23 | 20k | 7mo |
|
How to read a phase 2 result without treating it as a phase 3 result
The question in the title: How to read a phase 2 result without treating it as a phase 3 result I will give what I have already checked below so nobody repeats it. Session topic: FLOW ( N Engl J Med , 2024).…
|
+36 | 40 | 35k | 7mo |
|
Reverse causation in a cohort study of weight and outcome
On the subject in the title: Reverse causation in a cohort study of weight and outcome Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with FLOW ( N Engl J Med , 2024) and…
|
+10 | 14 | 11k | 7mo |
|
What "verified" means on our vendor pages, stated narrowly
What "verified" means on our vendor pages, stated narrowly — that is the question, and I have not found it answered plainly anywhere I have looked. I would like to talk about documentation quality as a…
|
+27 | 31 | 27k | 7mo |
|
Journal club: the retatrutide phase 2 obesity paper
Journal club: the retatrutide phase 2 obesity paper — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
|
+7 | 11 | 33k | 7mo |
|
Tracking that stops updating and then resumes
On the subject in the title: Tracking that stops updating and then resumes Working notes rather than a conclusion. A logistics question, since the answers here are usually better than anywhere else I have…
|
+58 | 62 | 1.9k | 7mo |
|
Documentation that appears only after payment
Documentation that appears only after payment Writing it up because I had to work it out twice and would rather nobody else did. I would like to talk about documentation quality as a signal, separately from…
|
+113 | 124 | 13k | 7mo |
|
What to include when your question involves arithmetic
What to include when your question involves arithmetic — that is the question, and I have not found it answered plainly anywhere I have looked. Question in the title. Context below, and I have tried to…
|
2 | 3.1k | 7mo | |
|
Follow-up: Glucagon receptor agonism in a weight-loss compound
Glucagon receptor agonism in a weight-loss compound Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means before I repeat it…
|
+5 | 9 | 21k | 7mo |
|
Selection into a registry and what it does to the estimate
Selection into a registry and what it does to the estimate — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it before posting; the…
|
2 | 55k | 7mo |